Product Information:

GABICA CR 330mg Tablets contain Pregabalin 330mg in a controlled-release (CR) formulation. Pregabalin is a gamma-aminobutyric acid (GABA) analog that binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters involved in neuropathic pain, seizure propagation, and anxiety.

This is the maximum approved strength of controlled-release pregabalin, designed for once-daily dosing in patients requiring intensified therapy with improved convenience and stable plasma levels over 24 hours.

⚠️ Note: GABICA CR 330mg is not interchangeable with immediate-release pregabalin on a mg-to-mg basis. It is intended only for patients already stabilized on lower doses.

Uses of (GABICA CR 330MG TABLETS):

1. Management of moderate to severe neuropathic pain (e.g., diabetic peripheral neuropathy, postherpetic neuralgia)
2. Adjunctive therapy in refractory partial-onset seizures in adults
3. Off-label use in generalized anxiety disorder (GAD) in select, treatment-resistant cases

Key Benefits of (GABICA CR 330MG TABLETS):

1. Once-daily dosing enhances adherence and reduces pill burden
2. Steady drug release minimizes peak-trough fluctuations, potentially lowering side effects like dizziness or sedation
3. Suitable for long-term maintenance in stable patients
4. Avoids multiple daily doses required with immediate-release formulations

How To Use (GABICA CR 330MG TABLETS):

1. Take once daily, preferably after an evening meal (food increases absorption by ~20%).
2. Swallow whole with water—do not crush, chew, split, or dissolve (this would disrupt the controlled-release mechanism and risk dose dumping).
3. Take at the same time each day.
4. Do not stop abruptly—taper gradually under medical supervision to avoid withdrawal symptoms (insomnia, headache, nausea, seizures, or rebound anxiety).

When Not to Use (GABICA CR 330MG TABLETS):

Do not use if you have:

1. Hypersensitivity to pregabalin or any excipients
2. History of angioedema with pregabalin
3. Severe renal impairment (CrCl <30 mL/min)—contraindicated due to lack of dose flexibility
4. Pregnancy or breastfeeding (unless clearly needed after thorough risk-benefit assessment)

Side Effects of (GABICA CR 330MG TABLETS):

Common: Dizziness, somnolence (drowsiness), dry mouth, peripheral edema (swelling in legs/feet), weight gain, blurred vision, fatigue.

Rare: Difficulty concentrating, mood changes, constipation.

Serious (rare but more likely at high doses):

1. Angioedema (facial, lip, tongue, or throat swelling—seek emergency care)
2. Suicidal thoughts or behavior (monitor closely for new or worsening depression)
3. Rhabdomyolysis (muscle pain, weakness, dark urine)
4. Worsening heart failure due to fluid retention
5. Discontinue and seek immediate medical help if serious reactions occur.

Dosage: (GABICA CR 330MG TABLETS):

1. Maintenance dose: 330mg once daily (evening)
2. Not a starting dose—must be titrated from lower strengths (e.g., 165mg)
3. Maximum daily dose: 330mg for CR formulation
4. Renal impairment: Contraindicated if CrCl <30 mL/min; not recommended if CrCl 30–59 mL/min
5. Elderly: Use with caution; assess renal function before initiation

Who It’s For (GABICA CR 330MG TABLETS):

Adults with severe, chronic neuropathic pain or refractory epilepsy who have responded well to lower doses of pregabalin and require optimized once-daily therapy. Not for treatment-naïve patients or acute conditions.

Warnings & Precautions:

1. May significantly impair driving or operating machinery—avoid until individual response is known
2. Monitor for weight gain, edema, cognitive effects, and mood changes
3. Use cautiously in patients with heart failure, diabetes, or history of substance abuse
4. High potential for misuse or dependence—prescribe only when benefits outweigh risks
5. Not bioequivalent to immediate-release pregabalin—do not substitute without physician oversight

Drug Interactions:

1. CNS depressants (opioids, benzodiazepines, alcohol): Additive sedation and life-threatening respiratory depression
2. ACE inhibitors: Possible increased risk of angioedema
3. Thiazolidinediones (e.g., pioglitazone, rosiglitazone): May exacerbate fluid retention and heart failure
4. Always inform your doctor about all medications and supplements.

Additional Information:

Store below 30°C in a dry place, protected from light and moisture. Keep out of reach of children. Do not use after the expiration date on the blister pack. Available by prescription only in Pakistan.